Unknown PHASE2 INTERVENTIONAL 2-arm NCT04969029

Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Randomized, Controlled Phase II Study of Immunotherapy Versus Standard Chemotherapy as Adjuvant Therapy After Surgery for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Adjuvant Therapy Colon Cancer Immunotherapy MSI-H

Interventions Tirelizumab

Updated 4 times since 2021 Last updated: Jul 11, 2021 Started: Jun 1, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adjuvant Therapy and Colon Cancer and is currently ongoing. Tianjin Medical University Cancer Institute and Hospital leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Jan 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Sep 2021 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianjin Medical University Cancer Institute and Hospital

Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China